Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 CAD | +0.24% | +1.55% | +53.79% |
Mar. 15 | Transcript : Cipher Pharmaceuticals Inc., Q4 2023 Earnings Call, Mar 15, 2024 | |
Mar. 14 | Tranche Update on Cipher Pharmaceuticals Inc.'s Equity Buyback Plan announced on November 15, 2023. | CI |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company appears to be poorly valued given its net asset value.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Revenue estimates are regularly revised downwards for the current and coming years.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+53.79% | 150M | - | ||
+26.47% | 664B | C+ | ||
+24.95% | 567B | B | ||
-6.33% | 354B | C+ | ||
+19.35% | 330B | B- | ||
+4.23% | 286B | C+ | ||
+14.28% | 234B | B+ | ||
+4.62% | 199B | B- | ||
-9.73% | 196B | A+ | ||
-4.04% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CPH Stock
- Ratings Cipher Pharmaceuticals Inc.